Preclinical Evaluation of 99mTc-Labeled GRPR Antagonists maSSS/SES-PEG2-RM26 for Imaging of Prostate Cancer.

Ayman AbouzayedSara S RinneHamideh SabahnooJens SörensenVladimir ChernovVladimir Tolmachev Anna Orlova

Published in: Pharmaceutics (2021)

The GRPR antagonist maSSS-PEG2-RM26 is a promising GRPR-targeting agent that can be radiolabeled through a single-step with the generator-produced 99mTc and used for imaging of GRPR-expressing prostate cancer.

Keyphrases

prostate cancer
radical prostatectomy
high resolution
drug delivery
pet imaging
bone marrow
photodynamic therapy